Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
ACE Inhibitors (Lisinopril) / ARBs (Valsartan)
Treatment for Heart Failure
Typical Dosage: Lisinopril 2.5-5 mg daily up to 20-40 mg daily; Valsartan 20-40 mg BID up to 160 mg BID
Effectiveness
78%
Safety Score
70%
Clinical Trials
100
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
Lisinopril 2.5-5 mg daily up to 20-40 mg daily; Valsartan 20-40 mg BID up to 160 mg BID
Time to Effect
1-3 months
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
25(Treat 25 patients to see 1 additional successful outcome)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$150
Monitoring:$600
Side Effect Mgmt:$75
Total Annual:$825
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$5,000/QALY
QALYs Gained
0.9
Outcome-Based Costs
Cost per Responder
$1,833
Comparison vs No treatment
Cost Difference
$-1,200/year
Less expensive
QALY Difference
+0.90 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
ACE Inhibitors (Lisinopril) / ARBs (Valsartan) Outcomes
for Heart Failure
Efficacy Outcomes
Overall Effectiveness
+78%
Response Rate
+45%
Common Side Effects
Cough
+12%
Hypotension
+8%
Dizziness
+8%
Hyperkalemia
+4%
Angioedema
+0.2%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov